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Introduction
Extensive remodeling of the cardiac extracellular matrix (ECM) occurs during myocardial infarction. As an orchestrated response to heart damage, loss of myocardial mass due to ischemia induces cardiac fibrosis, mainly, but not only, mediated by the transdifferentiation of fibroblasts to myofibroblasts, with significant collagen production and deposition 1 . Since adult mammals have a limited capacity to regenerate the cardiomyocytes after cell death, this "reparative" fibrotic response constitutes the only way for the entire organ to preserve its structural integrity, avoid rupture and maintain its pumping capacity. However, this progressively leads to cardiac remodeling, increased tissue stiffness and propensity to arrhythmias and eventually to heart failure. Collagen is a relatively stiff material with a high tensile strength; therefore tissue stiffness is expected to increase upon collagen deposition following a MI. However, recent studies have shown that increased collagen production and deposition in itself is not always directly translated into increased stiffness, and that myocardial damage results not only in an increase in collagen content but also in structural qualitative changes in collagen network 2, 3 . One of the characteristic features of collagen is its extensive post-translational modifications, including proline and lysine hydroxylation, glycosylation of specific hydroxylysine residues, oxidative deamination of the -amino groups of peptidyl lysine/hydroxylysine in the telopeptide domains of the molecule, and subsequent intra/intermolecular covalent crosslinking 4 . Collagen tensile strength importantly relies on cross-linking 5 . This has led to the proposal that it is not only the amount of collagen that matters; it is the cross-linking which determines the stiffness. In fact, enhanced collagen cross-linking has been observed in the failing human heart, and it has been further demonstrated that it is the degree of cross-linking that significantly correlates with chamber stiffness 6, 7 . The members of the lysyl oxidase (LOX) family are responsible for initiating covalent cross-linking formation by catalyzing the oxidative deamination of lysine/hydroxylysine residues in collagen telopeptide domains, a process progressing into non-enzymatically condensation of aldehyde groups to form the mature cross-links. Five different LOX enzymes have been identified in mammals, the canonical LOX, and four LOX-like isoforms, LOXL1-4 8 . Abnormally increased expression of the active form of LOX and of LOX mRNA has been reported in the fibrotic myocardium of patients with heart disease 9 . LOX mRNA and protein have been also found to be upregulated in animal models of heart failure, including MI, together with a significant increase in collagen cross-linking and chamber stiffness 10, 11 .
Based on these clinical and experimental observations, it is conceivable that LOX upregulation may play a significant role in cardiac remodeling upon MI. Nevertheless, the specific contribution of the LOX family members in the response to MI and whether they play beneficial or detrimental roles during heart remodeling is virtually unknown. In this work, we aimed to assess the expression of LOX isoforms in a mouse model of MI, as well as to analyze the main cell type/s responsible for their expression. Finally, we studied the contribution of this family of enzymes to cardiac remodeling and function, as an obligate step in their validation as pharmacological target for post-MI treatment.
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Methods
A detailed description of the methods is provided in Supplementary material online.
Mouse model of myocardial infarction
MI was induced in C57BL/6 by permanently ligating the left coronary artery as previously described 12 . Control, uninfarcted animals were sham-operated. Cardiac function, chamber dilatation, and wall thickness were analyzed by transthoracic echocardiography 3 and 28 days after infarction, as well as in uninfarcted mice, using a Vevo 2100 high resolution ultrasound system equipped with a 30-MHz linear array transducer (Visualsonics, Toronto, Canada). For LOX inhibition studies, mice were treated either with aminopropionitrile (BAPN, 5 mg/kg body weight/day; Sigma-Aldrich, St. Louis, Missouri) (n=10 per group) or with a rabbit polyclonal antibody reported to specifically block LOX isoform (1 mg/kg body weight/twice weekly), injected intraperitoneally (n=5 per group) 13 . Control mice received PBS as vehicle for BAPN, or the same amount of control IgG (Sigma-Aldrich) for anti-LOX. In two experimental groups, BAPN treatment started either on the same day or eight days after MI. The administration of anti-LOX antibody was initiated eight days after MI. Both animal trials were ended at day 28 post-infarction. Animals were sacrificed by gradually filling the chamber with carbon dioxide. The investigation conforms to the principles of Laboratory Animal Care, which are formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health, 2011), and the Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
Histological and immunohistochemical studies
The extent of cardiac damage and fibrosis was assessed by standard histological and immunohistochemical methodologies. Immunohistochemical stainings and double immunofluorescence were performed using methods previously described 14 .
RNA extraction and quantitative real-time reverse-transcribed polymerase chain reaction
For RNA studies, heart tissue was snap-frozen in liquid nitrogen. Total RNA was extracted using the RNAeasy kit (Qiagen), the cDNA was synthesized (iScript cDNA synthesis kit, Bio-Rad, Hercules, California) and quantitative real time reverse-transcribed polymerase chain reaction (RT-PCR) was performed as described with off-the-shelf Taqman probes (Applied Biosystems, Foster City, California) 12 .
Collagen and collagen cross-linking analysis
Heart tissue portions were hydrolyzed (110°C, 24 hours) in 6 M HCl and collagen (hydroxyproline and proline) and mature trivalent cross-links, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP), analyzed as described previously 15 .
Culture of cardiac fibroblasts
Mice were sacrificed by gradually filling the chamber with carbon dioxide and cardiac fibroblasts were isolated from 8-week old mouse heart tissue using methods previously described 16 . Mouse cardiac fibroblasts were treated for time periods ranging from 8 to 48 hours with TGF-1 at 5 ng/ml under normoxic or hypoxic conditions (1% O2 tension, CVR-2015-551 6 Hypoxystation H35, Don Whitley, Shipley, England). At the end of the experimental period, total RNA or protein were extracted and analyzed following protocols previously described 14 .
Statistical Analysis
Data are presented as mean ± SE. In echocardiographic data, the same mice were analyzed 3 and 28 days post-infarction, with non-infarcted animals representing a different group of mice. To test for statistical significance, data were analyzed by one-or two-way ANOVA followed by Bonferroni post-test, or by unpaired t-test as indicated in the corresponding table and figure legends. Statistics was performed with GraphPad Prism 5.0 (La Jolla, California), and differences were considered statistically significant at P< 0.05.
Results

Increased LOX and LOXL expression after MI
In order to gain insight about the potential contribution of LOX family members to the heart response to MI, we established an infarct mouse model with permanent ligation of the left anterior descending artery. Cross-sections of the ventricles stained with Picrosirius red and visualized under brightfield light microscopy showed that coronary artery ligation resulted in large transmural infarcts with progressive accumulation of collagen and left ventricular wall thinning in the infarct area (Supp. Fig. 1A-C) . Interestingly, collagen visualization by Picrosirius red staining under polarized light showed long and highly aligned collagen fibers in the remodeled heart of mice at 7-28 days post injury, in marked contrast to mice with no infarct or those sacrificed 3 days after coronary ligation, which displayed an almost black background (Fig. 1A) . Quantification of immature (greenish-yellow) and mature (reddishorange) collagen revealed a progressive accumulation of mature fibers when compared to immature collagen (Fig. 1B) . While the presence of highly birefringent collagen scaffolds does not directly demonstrate enhanced cross-linking, these observations indicate the potential involvement of LOX upregulation in the formation of mature collagen bundles in the fibrotic scar of the infarcted heart. In order to analyze the expression profile of LOX family members in response to MI, three heart regions were defined corresponding to the scar (infarct), the peri-infarct (border), and the sites distant from the infarct area (remote), as indicated in the micrograph taken 28 days post injury (Supp. Fig. 1A ). Total RNA was extracted from these regions and analyzed by real time quantitative RT-PCR. Compared with uninjured hearts, MI induced increases in the expression of the whole set of LOX genes in all areas studied, with higher induction rates in the infarct, diminishing gradually in border and remote zones (Fig. 1C ). Gene expression increases were detectable at 3 days post injury and peaked between 3-7 days for all of the isoforms. These results were confirmed by immunohistochemical analysis for LOX, LOXL2 and LOXL4 at 7 days after coronary ligation as compared with control ( Fig. 2A, 2B ). Available antibodies for LOXL1 and LOXL3 did not work in our hands (data not shown). Myofibroblasts dominate the regulation of collagen turnover in the injured heart 1 . In order to study whether myofibroblasts are the main source for the expression of LOX after myocardial infarction, consecutive cross-sections of control and infarcted hearts (7 days post-MI) were analyzed for the expression of the canonical LOX, the most highly induced LOX isoform in our experimental conditions, and of the myofibroblast marker -smooth muscle actin (-SMA). As shown in Fig. 3A , LOX expression was found to be associated with areas of extensive tissue remodeling with the presence of positively birefringent collagen fibers, partially overlapping with extravascular -SMA-positive cells. Staining with the cardiomyocyte-specific marker cardiac troponin I (cTNI) showed a faint labeling of LOX in cTNI-rich regions around the injured heart, whereas CD45-positive leukocytes seems not to display specific LOX staining (Supp. Fig. 2 ). The expression of LOX by extravascular -SMA-positive myofibroblasts was also studied by immunofluorescence. As shown in Fig. 3B , positive co-localization of LOX and -SMA was observed in the injured heart, but we also found a number of LOX-expressing cells that were negative (or very low stained) for -SMA. Taken together, these results show that LOX family members are highly induced in response to myocardial infarction, presumably contributing to cardiac remodeling by collagen crosslinking, and that myofibroblasts constitute a cell source for the expression of LOX.
TGF- and hypoxia induce LOX and LOXL expression in cardiac fibroblasts
Next, we investigated whether the induction of LOX genes can be recapitulated in cardiac fibroblasts and analyzed the signal transduction pathways potentially involved. Previous work from different groups including ours has shown that TGF- and hypoxia are important stimuli for LOX/L expression in a number of cells and tissues [17] [18] [19] [20] . Clinical and experimental evidence point also to a role for TGF--and hypoxia-dependent pathways in the heart response to myocardial infarction [21] [22] [23] [24] . Accordingly, we found that TGF--and hypoxiadependent pathways were activated in our model of MI as assessed by phospho-Smad and HIF1 staining, respectively ( Fig. 4A and B) . We then isolated cardiac fibroblasts from mouse ventricles, exposed them under culture conditions to 5 ng/ml of TGF-1 and hypoxia (1% O2 tension) or both, and analyzed the expression of LOX/L isoforms. Under our experimental conditions, only TGF- stimulus was able to promote myofibroblast differentiation, as assessed by -SMA expression (Supp. Fig. 3 ). As shown in Fig. 4C , TGF- and hypoxia induced the expression of the whole set of LOX isoforms, except for LOXL1 by TGF-1, as assessed by quantitative RT-PCR. The combination of both stimuli was particularly effective to upregulate the expression of LOX and LOXL2. The induction of the canonical LOX mRNA is followed by protein expression and accumulation in the cell supernatant, as shown in Fig. 4D and E. Taken together, these results indicate that the induction of LOX isoforms can be recapitulated in vitro by activation of TGF--and hypoxiadependent pathways in cardiac fibroblasts.
LOX activity inhibition improves cardiac function after MI
We show here that LOX/L enzymes are induced as a response to MI at 3-7 days after injury.
To determine the role of LOX in heart remodeling following MI, we studied the effect of the inhibition of LOX activity with the small molecule -aminopropionitrile (BAPN) in the MI mouse model. BAPN (5 mg/kg body weight/day) was administered daily to control animals (sham-operated) and to infarcted mice, starting 8 days after surgery. The extent of collagen content and cross-linking was studied in the scar area by biochemical and histological techniques in the control and BAPN-receiving animals. HPLC-based biochemical evaluation showed a modest though significant increase in the amount of the major stable mature crosslink 28 days post-MI, as represented by hydroxylysylpyridinoline (HP)/triple helix, together with an increase in collagen accumulation, expressed as hydroxyproline/proline ratio ( Fig. 5A  and B ). LOX inhibition with BAPN resulted in a significant reduction in both collagen crosslinking and content. Interestingly, careful analysis under polarized light of the accumulated collagen revealed a diminished presence of orange-red mature collagen bundles in control mice compared to the green-yellow fibers observed in BAPN-treated ( Fig. 5C and D) . Heart tissue sections stained with Picrosirius red showed a significant reduction in the extent of the fibrotic scar area in BAPN-treated mice 28 days post-MI, as well as a diminished infarct length ( Fig. 5E and F) . In agreement with these results, BAPN treatment resulted in a reduction in the number of ventricular wall segments with reduced motility as measured by echocardiography, suggesting that BAPN-treated animals have reduced infarct expansion compared to control animals (Table 1) . We next analyzed whether BAPN treatment altered the expression of LOX isoforms and certain metalloproteases (MMP) reported to be involved in the heart response to damage 25 . As shown in Supp. Fig. 4 , except LOXL1 and MMP9, the expression of these matrix remodeling enzymes was found to be upregulated at 28 days postinfarction, and did not change upon BAPN treatment. Interestingly, the expression of the metalloprotease inhibitor TIMP4 was diminished upon MI, and this downregulation was not observed in infarcted mice under BAPN administration. To assess cardiac function we carried out echocardiographic analysis 3 and 28 days postinjury as well as in uninjured mice. BAPN did not significantly alter cardiac function in control animals (Table 2) . However, BAPN administration, starting either 8 days after MI or on the same day of the intervention, reduced ventricular dilatation and improved ejection fraction 28 days post injury, compared to untreated animals. Improved function was accompanied by a reduction in the heart weight/body weight ratio (Supp . Table. 
1).
Only a few number of molecules have been identified as potential LOX inhibitors (being BAPN the most widely used compound), and even fewer as selectively blocking one particular isoform 26, 27 . To confirm the role of LOX in post-MI cardiac remodeling, we carried out additional experiments using a rabbit polyclonal antibody that blocks canonical LOX activity in vivo 28 . As shown in Fig. 6 , mice subjected to MI and receiving anti-LOX antibody displayed reduced cardiac fibrosis and diminished scar area and infarct size, compared with mice treated with rabbit IgG as a control. Mice treated with anti-LOX antibody displayed significantly reduced ventricular dilatation and improved ejection fraction 28 days post-infarction. This was paralleled by a reduction in the number of ventricular wall segments with reduced motility as measured by echocardiography ( Tables 3 and 4 ). Taken together our results indicate that the inhibition of LOX enzymatic activity, particularly that of the canonical LOX, impairs the formation of a mature collagen matrix upon myocardial infarction, and that this is associated with a beneficial effect on cardiac remodeling and function.
Discussion
The family of LOX enzymes has attracted considerable interest in recent years as their members have been associated with several diseases, particularly in the vascular system and in tumorigenesis 29, 30 . Although biological roles beyond ECM remodeling have been described for LOX members, such as chromatin regulation or cellular chemotaxis, most reported actions in the vascular and cancer settings invoke the capacity of these enzymes to contribute to ECM building and maintenance 29, 31 . In the cardiovascular system, where the ECM plays an essential role in providing the biomechanical properties, pioneering work by Lerman et al. reported that LOX activity increased during the healing response to acute myocardial infarction in rabbits 32 . Augmented expression of the canonical LOX has been also reported during the myocardial fibrotic response occurring in spontaneously hypertensive rats (SHR), an observation linked to enhanced collagen cross-linking and deposition 9 . Additional experimental models, such as C57/BL6 mice under a high fat and carbohydrate diet, a model of metabolic syndrome, or rhesus monkeys subjected to left anterior descending artery ligation, developed myocardial fibrosis with increases in collagen cross-linking and LOX activity and/or expression 33, 34 . Clinically, myocardial fibrosis in patients with hypertensive heart disease and chronic heart failure is associated with enhanced LOX expression and matrix cross-linking 9 . These studies investigating the role of LOX in heart diseases were mainly focused on the analysis of the expression of the canonical LOX, with no or very little information on the remaining isoforms. Here we show, to our knowledge for the first time, that the whole set of LOX genes were strongly upregulated in an infarct mouse model. Coordinated expression of all the LOX family members suggests that common signaling pathways are triggered to induce their expression during heart response to injury. TGF- and hypoxia have been previously shown to be important regulators of the expression of multiple LOX family members in other cell and tissue contexts 18, 20 . Here we also show that, in agreement with previous studies, these signaling pathways were indeed activated after myocardial infarction and promoted the expression of LOX/L in cultured cardiac fibroblasts, the main cell type giving rise to myofibroblasts in the fibrotic heart 21-24 . To this respect, although TGF- has been described to have a preeminent role in gene expression changes occurring during cardiac fibrosis, tissue hypoxia is a common feature of different conditions leading to cardiac fibrosis, including myocardial infarction and pressure-or volume-overload, and has been reported to induce ECM accumulation and myofibroblast differentiation in cardiac fibroblasts [35] [36] [37] . The acquisition of a contractile phenotype by expression of -SMA is widely used to identify differentiated myofibroblasts 38 . Here we describe that extravascular -SMA-positive cells constitute a cell source for the expression of the canonical LOX isoform, the most highly upregulated isoform upon myocardial damage 39 . It should be however noted that some cells negative or low stained for -SMA were also found to contribute to LOX expression. While the nature of these cells is at present unknown, different authors have reported a significant developmental heterogeneity in the origin of cardiac fibroblasts, with the presence of fibroblast cell lineages not expressing -SMA 40-42 . To make this issue even more complicated, cardiomyocytes have been reported to express LOXL1 upon stimulation with hypertrophic agonists, and T-lymphocytes have been described to regulate cardiac fibroblast LOX expression 43, 44 . In fact, our study also detected upregulation of expression of LOX in cardiomyocytes in the infarcted region; nevertheless this expression was considerably lower than that observed in myofibroblasts. Deposition and cross-linking of fibrillar collagen during the heart response to damage confers strength that opposes to scar and chamber deformation, but has also a tremendous impact on the mechanical and electrical properties of the myocardium. Antifibrotic and cardioprotective strategies have extensively focused on the attenuation of the fibrotic response 45, 46 . Given that the activation of the TGF- signaling plays an important role in the initiation and progression of the fibrotic process, a number of strategies have been established to block or mitigate this signaling pathway in order to reduce cardiac remodeling, unfortunately, without a clear answer. While some studies have reported detrimental effects of TGF- inhibition in a MI experimental model, other works described that TGF- signaling blockade by ALK5 inhibition successfully ameliorated myocardial collagen accumulation and cardiac dysfunction 47, 48 . More recently, a small molecule inhibiting ALK5 has been reported to improve cardiac function, and to diminish collagen and collagen cross-linking accumulation 49 . This is in agreement with reports describing the capacity of TGF- inhibitory peptides to improve cardiac function, in association with reduced collagen cross-linking and LOX expression, in experimental models of pressure overload, though this reflects a distinct clinical condition, presumably being governed by different pathogenetic mechanisms 9 . Whereas there is still some controversy, these findings support TGF- signaling blockade as an effective therapy to prevent cardiac dysfunction. Nevertheless, their translation to the clinical setting is challenging due to the pleiotropic nature of TGF- and its modulatory functions of the immune and inflammatory responses. Specific intervention of TGF- downstream targets contributing to tissue fibrosis might represent more realistic options for the clinical treatment, such as the inhibition of LOX-mediated matrix crosslinking. Using BAPN, it was previously shown that inhibition of LOX enzymatic activity decreased chamber and myocardial stiffness in pigs, therefore proving that these enzymes are important determinants of the biomechanical properties of the intact heart 50 . Upon heart damage, inhibition of LOX activity impaired the accumulation of collagen in a model of cardiac hypertrophy in rats, and more recently, BAPN reduced myocardial fibrosis in a mouse model of aging 51, 52 . While these experiments anticipated the potential use of LOX inhibitors for the treatment of heart disease, the specific contribution of LOX enzymes to cardiac dysfunction in disease models had not been clarified. Here we show that BAPN administration, starting either on the day of the coronary occlusion or 8 days after, reduced the accumulation of mature collagen after chronic MI and this effect was accompanied by reduced ventricular remodeling and improved cardiac function. Although ECM production and maturation is necessary to prevent cardiac rupture after MI, excessive matrix stiffness is associated with increased ventricular dilatation and reduced cardiac function in chronic MI. Based on our observations, LOX enzymes seem to play an important role in the tissue response to damage, and, therefore, LOX inhibitors could be of potential clinical application to treat post-infarction remodeling. Nevertheless, the clinical applicability of LOX inhibition in fibrotic and tumorigenic settings has been seriously questioned due to potential side effects and the lack of selective/specific inhibitors 27 . In this line, BAPN is also referred to be the main factor responsible for osteolathyrism, defined as bone and tissue weakening associated to dietary consumption of seeds of Lathyrus sativus or grass pea, this action relying on its capacity to inhibit LOX activity 53 . To this respect, we did not observe in BAPN-treated mice any particular case of cardiac rupture, nor the formation of aortic aneurysms, one of the clinical manifestations described to be associated to LOX inhibition 54 . In fact, human pilot studies using BAPN in specific fibrosis-like pathologies, such as the complications associated to filtration surgery in glaucoma patients 55 , have been carried out without serious side effects, and therefore, clinical suitability might be reached if safe dosage and time for treatment parameters are determined. Although decades of research have provided sufficient knowledge to confirm the fundamental role of LOX family members in several pathophysiological scenarios, only a few number of molecules have been characterized as potential LOX inhibitors (being BAPN the most widely used), and even fewer as selectively blocking one particular isoform 26, 27 . Here we show that specific inhibition of the canonical LOX isoform by using a blocking antibody reduced cardiac fibrosis and infarct expansion, leading to a significant improvement in cardiac remodeling and function and suggesting a preeminent role of this isoform in post-MI remodeling. To this respect, the relevance of this enzyme in cardiac pathophysiology has been recently recognized as the matricellular protein, osteopontin, found to be upregulated during myocardial remodeling in heart failure patients, was reported to promote cardiac fibrosis through activation of the expression and activity of LOX 56 . In conclusion, our results show that LOX family members are highly induced during the response to myocardial infarction and play a significant role in the development of cardiac fibrosis, presumably by activation of TGF--and hypoxia-dependent pathways in cardiac fibroblasts. We also show that the interference with the enzymatic activity of LOX proteins, particularly of the canonical LOX isoform, reduces ventricular remodeling and improves cardiac function in a mouse model of MI, and therefore we believe that this family of enzymes may represent a potential therapeutic target in cardiac fibrosis and post-ischemic heart failure. Nevertheless, more research, including the design and development of better inhibitors as well as additional in vivo analysis of potential side effects, is demanded in order to consider this family of proteins as a target for clinical intervention.
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